Synta, Madrigal deal

Madrigal and a subsidiary of Synta will reverse-merge as a company focused on non-alcoholic steatohepatitis (NASH), cardiovascular and metabolic diseases. The combined, publicly traded company will retain Madrigal’s name. This year, the merged company expects to start Phase II testing on lead compound MGL-3196 for NASH and heterozygous familial hypercholesterolemia (HeFH) and a smaller Phase IIa trial in homozygous familial hypercholesterolemia. Madrigal has exclusive, worldwide rights to the small molecule selective agonist of thyroid hormone receptor beta from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland). ...